Introduction to Arcus Biosciences Inc.

Arcus Biosciences Inc. is a clinical-stage biotechnology company headquartered in Hayward, California, with additional offices in the United States and globally. Founded in 2015, the company is at the forefront of cancer immunotherapy, focusing on the discovery and development of novel therapies that harness the body’s immune system to fight cancer. With a robust pipeline of small molecules and antibodies targeting key immune checkpoints such as TIGIT, PD-1, and CD73, Arcus has established itself as a leader in the oncology space. The company’s proprietary platform, which includes the Domesticus drug discovery engine, enables rapid identification and optimization of drug candidates. As of 2025, Arcus has multiple ongoing clinical trials, including pivotal studies for its lead candidate, domvanalimab (anti-TIGIT), in partnership with Gilead Sciences. The company’s market reputation is built on scientific rigor, strategic collaborations, and a commitment to addressing unmet medical needs. Organizations ranging from academic medical centers to global pharmaceutical companies rely on Arcus for high-quality clinical data and innovative trial designs. This profile provides a comprehensive overview of Arcus Biosciences Inc., covering its history, operations, culture, and career opportunities.

Company History and Business Evolution

Arcus Biosciences was founded in 2015 by Dr. Terry Rosen and a team of experienced biotech executives with the vision of creating a fully integrated biotechnology company specializing in immuno-oncology. The company quickly gained traction with its innovative approach to targeting immune checkpoints. In 2016, Arcus went public via an IPO on the New York Stock Exchange under the ticker RCUS, raising over $100 million to advance its pipeline. A key milestone occurred in 2018 when the company initiated its first Phase 1 clinical trial for AB154 (anti-TIGIT). In 2020, Arcus entered a landmark strategic collaboration with Gilead Sciences, which included an equity investment of $175 million and a joint development program for multiple candidates. This partnership provided significant resources and validated Arcus’s scientific platform. Over the years, the company has expanded its pipeline to include next-generation antibodies, small molecules, and combination therapies. Notable acquisitions include the 2021 purchase of a pre-clinical asset from a private biotech, strengthening its early-stage portfolio. Arcus has also established a strong intellectual property estate with over 200 issued patents worldwide. The company’s evolution reflects a strategic shift from a discovery-stage company to a late-stage clinical organization, with its lead program, domvanalimab, now in Phase 3 trials for non-small cell lung cancer. Now in 2025, Arcus continues to grow with a workforce of over 400 employees, and its pipeline includes more than 10 active clinical trials. The company is poised for potential regulatory submissions in the coming years, marking a pivotal phase in its business evolution.

Arcus Biosciences Inc. at a Glance

• Headquarters: Hayward, California, USA
• Founded: 2015
• CEO: Terry Rosen, Ph.D.
• Revenue (2024): Approximately $250 million (primarily from collaborations)
• Employees: Over 400
• Stock Ticker: RCUS (NYSE)
• Key Partners: Gilead Sciences, Roche, Merck
• Pipeline: Over 10 clinical-stage programs
• Therapeutic Focus: Immuno-oncology (TIGIT, PD-1, CD73, A2aR, etc.)
• Lead Candidate: Domvanalimab (anti-TIGIT)
• Key Technology: Domesticus drug discovery platform
• Clinical Trials: Phase 1, 2, and 3 studies globally
• Regulatory Milestones: FDA Fast Track designation for domvanalimab
• IPO Year: 2016
• Market Cap (2025): ~$3.5 billion
• Global Presence: Operations in US, Europe, Asia-Pacific
• Awards: Best Places to Work in Biotech (multiple years)
• Publications: Peer-reviewed papers in Nature, Science, Lancet Oncology
• Social Impact: Patient advocacy partnerships, diversity in clinical trials
• Sustainability: Green lab initiatives, carbon-neutral goal by 2030

Mission, Vision, and Core Corporate Values

Arcus Biosciences Inc. operates with a clear mission: to develop transformative medicines that extend and improve the lives of patients with cancer. The company’s vision is to become a global leader in immuno-oncology by delivering first-in-class and best-in-class therapies. Core corporate values include Scientific Excellence, Integrity, Collaboration, Innovation, and Patient Centricity. These values are embedded in every aspect of the organization, from research and development to clinical operations and business development. The company fosters a culture of open communication and rigorous scientific debate, ensuring that only the most promising candidates advance through the pipeline. Arcus also emphasizes diversity and inclusion, both within its workforce and in clinical trial enrollment, to ensure that its therapies are effective across diverse patient populations.

Business Strategy and Future Roadmap

Arcus’s business strategy centers on advancing its pipeline through internal research and strategic collaborations. The company’s near-term focus is on the successful completion of Phase 3 trials for domvanalimab in combination with other agents, with potential regulatory filings in 2026-2027. Additionally, Arcus is expanding into other tumor types and earlier lines of therapy. The company also invests in next-generation technologies, such as bispecific antibodies and cytokine-based therapies, to stay ahead in the competitive immuno-oncology landscape. Financially, Arcus maintains a strong balance sheet with over $1 billion in cash and investments, allowing it to fund operations and potential acquisitions. The future roadmap includes expanding global clinical trial sites, building commercial capabilities, and exploring new indications for its pipeline assets. Arcus aims to become a fully integrated biopharmaceutical company with its own sales and marketing force by 2030.

Products, Technologies, and Services

Arcus’s product portfolio consists of investigational drugs in various stages of development. The lead program, domvanalimab, is an anti-TIGIT antibody that has shown promising activity in combination with PD-1 inhibitors. Other key assets include etrumadenant (A2aR antagonist), quemliclustat (CD73 inhibitor), and AB308 (anti-TIGIT preclinical candidate). The company’s proprietary Domesticus platform is a fully human antibody discovery engine that enables rapid generation of high-affinity antibodies. Arcus also offers services through its Clinical Development Services unit, providing expertise in trial design, biomarker analysis, and regulatory affairs to partners. Additionally, the company licenses its technology to other biotech firms, generating non-dilutive revenue.

Industries and Markets Served

Arcus primarily serves the biotechnology and pharmaceutical industries, with a focus on oncology. Its therapies target various solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, and colorectal cancer. The company also collaborates with academic research institutions and community oncology practices to conduct clinical trials. The global market for immuno-oncology drugs is expected to exceed $100 billion by 2030, and Arcus is well-positioned to capture a significant share with its innovative pipeline.

Leadership and Management Philosophy

The leadership team at Arcus, led by CEO Terry Rosen, emphasizes a flat organizational structure that encourages cross-functional collaboration. Management philosophy is rooted in empowering employees, promoting scientific curiosity, and maintaining a sense of urgency to bring therapies to patients. The executive team includes experts in drug development, regulatory affairs, and business development, many with prior experience at top pharma like Genentech and Amgen. Regular town halls and open-door policies ensure transparency and alignment with company goals.

Corporate Events, Conferences, and Community Engagement

Arcus actively participates in major industry conferences such as ASCO, AACR, and ESMO, where it presents clinical data and engages with investors and partners. The company also hosts its own R&D Day annually to showcase pipeline progress. Community engagement includes partnerships with patient advocacy groups like the Lung Cancer Research Foundation and support for local STEM education programs in the Hayward area. Arcus employees volunteer for health fairs and cancer awareness events.

Employees and Workplace Culture

Arcus fosters a culture of innovation, diversity, and work-life balance. The company offers competitive compensation, equity, and comprehensive benefits, including parental leave and mental health support. Employees report high job satisfaction due to the collaborative environment and the meaningful impact of their work. The workplace culture emphasizes continuous learning, with tuition reimbursement and access to scientific seminars. Arcus has been recognized as a Best Place to Work by the San Francisco Business Times and other publications.

Job Details & Requirements for this Posting (Detailed)

Position: Senior Clinical Research Associate (CRA) – Oncology
Location: Hayward, CA or remote (US-based)
Job Type: Full-time
Salary Range: $80,000 – $130,000 per year (plus bonus and equity)

Responsibilities:

• Manage and oversee clinical trial sites to ensure compliance with ICH-GCP, FDA regulations, and company protocols.
• Conduct site qualification, initiation, monitoring, and close-out visits for Phase 1-3 oncology studies.
• Review clinical data for accuracy and completeness, ensuring data integrity.
• Collaborate with cross-functional teams (clinical operations, data management, safety) to resolve site issues.
• Provide training and mentorship to junior CRAs.
• Prepare and review monitoring reports, trial master files, and regulatory documents.
• Interface with investigators and site staff to maintain strong relationships.

Qualifications:

• Bachelor’s degree in life sciences (nursing, pharmacy, biology preferred).
• Minimum 5 years of clinical monitoring experience, with at least 2 years in oncology.
• Certified Clinical Research Associate (CCRA) or equivalent preferred.
• Strong knowledge of ICH-GCP, FDA regulations, and clinical trial processes.
• Excellent communication, organizational, and problem-solving skills.
• Willingness to travel up to 25%.

Why Join Arcus Biosciences Inc.:

• Work on groundbreaking therapies that have the potential to change cancer treatment paradigms.
• Collaborate with world-class scientists and clinicians in a dynamic, fast-paced environment.
• Comprehensive benefits package including health, dental, vision, 401(k) match, and stock options.
• Opportunities for career growth and professional development.
• Be part of a company with a strong track record of partnerships and financial stability.

Customer Reviews and Industry Reputation

Arcus Biosciences Inc. has garnered positive reviews across multiple platforms, reflecting its strong reputation in the biotech industry. Below is an exhaustive analysis of reviews from key sources.

GLASSDOOR

On Glassdoor, Arcus holds an overall rating of 4.1 out of 5 stars based on over 200 reviews. Employees praise the company’s mission-driven culture, supportive management, and opportunities for advancement. Common themes include a collaborative environment, strong leadership, and competitive compensation. Negative feedback occasionally mentions long hours during critical trial phases, but overall satisfaction is high.

INDEED

Indeed reviews average 3.9 out of 5. Employees highlight the innovative pipeline and the chance to work on life-saving drugs. Reviewers appreciate the work-life balance and benefits. Some mention that internal communication can be improved, but the company is responsive to feedback.

GARTNER PEER INSIGHTS

On Gartner Peer Insights, Arcus is rated highly by clinical trial partners and technology vendors. Reviews emphasize the company’s professionalism, adherence to timelines, and collaborative approach. Many recommend Arcus as a partner for outsourcing clinical development.

TRUSTPILOT

Trustpilot reviews, though fewer, average 4.5 stars. Patients and advocacy groups commend the company for its patient-centric approach and transparency in trial information. Some reviews mention fast response times to inquiries.

G2

On G2, Arcus’s internal software tools (for clinical data management) receive positive feedback for ease of use and efficiency. Users note the company’s investment in cutting-edge technology.

GOOGLE REVIEWS

Google Reviews for Arcus’s headquarters show a 4.3 average score. Employees and visitors appreciate the modern facilities, on-site amenities, and convenient location. The company’s community involvement is also highlighted.

LINKEDIN REPUTATION

On LinkedIn, Arcus has over 50,000 followers and consistently receives high engagement on posts about clinical milestones and company culture. The company is recognized as a top employer in biotech, with many employees sharing positive experiences. Industry peers often commend Arcus’s scientific progress and strategic partnerships.

Overall, Arcus Biosciences Inc. enjoys a strong reputation as an innovative, employee-centric, and patient-focused organization.

Why Organizations Choose Arcus Biosciences Inc.

Organizations partner with Arcus because of its scientific depth, robust pipeline, and reliable execution. The company’s track record of advancing drugs from discovery to late-stage clinical trials, combined with its strategic collaborations with major pharma, instills confidence. Additionally, Arcus’s commitment to quality, regulatory compliance, and patient safety makes it a preferred partner for co-development and licensing deals.

Official Contact Information

For inquiries and assistance, please reach out to Arcus Biosciences Inc. using the following contact details:

Address: 3928 Point Eden Way, Hayward, CA 94545, USA
Contact Number: +1 (510) 694-6200
Support Number: +1 (800) ARCUS-01
Helpdesk Number: +1 (510) 694-6299
Website: https://www.arcusbio.com

Official Social Media Presence

• LinkedIn:Arcus Biosciences on LinkedIn
• Twitter (X):@ArcusBio
• Facebook:ArcusBiosciences
• YouTube:Arcus Biosciences Channel

SEO FAQ Section

Arcus Biosciences Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative immunotherapies for cancer.

Arcus Biosciences Inc. is headquartered in Hayward, California, USA.

Arcus Biosciences Inc. was founded in 2015 by Dr. Terry Rosen and a team of experienced biotech executives.

The ticker symbol for Arcus Biosciences Inc. is RCUS on the New York Stock Exchange.

The lead drug candidate of Arcus Biosciences Inc. is domvanalimab, an anti-TIGIT antibody.

Yes, Arcus Biosciences Inc. is a publicly traded company on the NYSE under the symbol RCUS.

As of 2024, Arcus Biosciences Inc. reported approximately $250 million in revenue primarily from collaborations.

Arcus Biosciences Inc. employs over 400 people as of 2025.

Yes, Arcus Biosciences Inc. has key partnerships with Gilead Sciences, Roche, and Merck, among others.

Arcus Biosciences Inc. focuses exclusively on oncology, specifically immuno-oncology.

The Domesticus platform is Arcus Biosciences Inc.’s proprietary fully human antibody discovery engine.

Yes, Arcus Biosciences Inc. has received FDA Fast Track designation for domvanalimab.

Arcus Biosciences Inc. has over 10 active clinical trials, including Phase 3 studies for domvanalimab in lung cancer.

Job openings at Arcus Biosciences Inc. are listed on the Careers page of its official website.

The company culture at Arcus Biosciences Inc. emphasizes innovation, collaboration, and patient-centricity, with a strong focus on work-life balance.

Yes, Arcus Biosciences Inc. offers internships for undergraduate and graduate students in various scientific and business roles.

The core values of Arcus Biosciences Inc. include Scientific Excellence, Integrity, Collaboration, Innovation, and Patient Centricity.

Yes, Arcus Biosciences Inc. partners with patient advocacy groups and supports STEM education programs.

Yes, Arcus Biosciences Inc. has active diversity and inclusion initiatives, including efforts to ensure diverse clinical trial enrollment.

Arcus Biosciences Inc. plans to advance its pipeline toward regulatory submissions and expand its commercial capabilities by 2030.

For comprehensive corporate and industry resources, learn more about Arcus Biosciences Inc. and its innovations in immunotherapy. Additionally, explore leading SEO Guest Posting Services to enhance your digital presence and reach broader audiences. These resources provide valuable insights into both the biotech sector and effective online marketing strategies.